Effect of Human Menopausal Gonadotrophin (HMG) therapy on fertility of infertile males

Frequency of fertility in unexplained male infertility referred to Urology clinic of Rafsanjan University of medical sciences after Human Menopausal Gonadotrophin (HMG) therapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150317021497N5

Enrollment

Registered

2019-02-24

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Male infertility

Interventions

Intervention group: Injection of 2 ampule of HMG (75000 unit) to 8 dose.

Eligibility

Sex/Gender

Male

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: unexplained infertility 2 years since marriage Age 25-40 years Men

Exclusion criteria

Exclusion criteria: Wife Infertility

Design outcomes

Primary

Measure	Time frame
Frequency of fertility. Timepoint: 3 months after beginning drug use. Method of measurement: Checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Nazari

Rafsanjan University of Medical Sciences

mrmokhtaree@yahoo.com+98 34 3426 0080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026